Compounded GLP-1 Legal Status and Shortage Rules | telos rx
Couple holding hands while walking up a sunlit grassy hill under a clear blue sky
← Back to blog
cc-176

Compounded GLP-1 Legal Status: Compounding Rules Explained

By telos rx Editorial Team

Compounded GLP-1 legal status depends on federal compounding rules, not a single yes or no. Semaglutide and tirzepatide are off FDA's shortage list, so compounders must meet stricter conditions. See how telos rx approaches GLP-1 care.

Written by the telos rx Editorial Team. Last reviewed: 20 November 2026.

If you have read headlines about compounded semaglutide or tirzepatide, you have probably seen mixed messages. Some say compounding has ended. Others say nothing changed. Neither is quite right.

This guide explains what FDA has said, what the shortage decisions changed and how to check a provider. We checked every FDA source on 20 November 2026. Rules can change, so read this as a snapshot.

What compounding means

Compounding is when a licensed pharmacist prepares a medicine for a specific patient. It needs a valid prescription. Compounded GLP-1s use the same active ingredients as branded drugs such as Wegovy and Zepbound.

They are different products. Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness or quality before they are sold. They are not better than, or equal to, the branded versions.

Two kinds of compounders

Federal law sets out two main routes. They follow different rules and have different regulators.

  • State-licensed compounding pharmacies. These prepare medicine for individual patients with a prescription. According to FDA's compounding questions and answers, state boards of pharmacy carry most of the day-to-day oversight.
  • Outsourcing facilities. These register with FDA, follow current good manufacturing practice and are inspected by FDA on a risk-based schedule.

The National Association of Boards of Pharmacy (NABP) brings state boards together and runs programs that help the public check online pharmacies. Your own state board can confirm whether a pharmacy holds a license.

Why the shortage list mattered

From 2022, demand for semaglutide and tirzepatide outran supply. Both sat on FDA's drug shortage list. While a drug is in shortage, compounders have more room to prepare versions of it.

That is why compounded GLP-1s grew so fast. When the shortages ended, that extra room ended too.

The FDA timeline at a glance

Here is what FDA posted on its GLP-1 compounding policy page, checked on 20 November 2026.

Date What FDA announced What it meant
2 October 2024 FDA said the tirzepatide injection shortage was resolved FDA later re-evaluated this decision
19 December 2024 FDA re-evaluated and again found the tirzepatide shortage resolved A transition window began for compounders
21 February 2025 FDA found the semaglutide injection shortage resolved A transition window began for compounders
Spring 2025 Court rulings went FDA's way and the windows closed Shortage-based compounding of copies ended
1 April 2026 FDA reminded compounders of the conditions they must meet Neither drug is on the shortage list

FDA gave compounders transition windows to avoid disrupting patients. Those windows have now closed.

The essentially-a-copy rule

This is the heart of the current rules. A state-licensed pharmacy may not compound, regularly or in large amounts, products that are essentially copies of a drug that is commercially available.

FDA's April 2026 reminder says a compounded product counts as a copy when both of these are true:

  • It has the same active ingredient in the same, similar or easily swapped strength.
  • The commercial drug can be used by the same route, such as injection.

There is an exception. A prescriber can decide and document that a change makes a significant difference for an identified patient. That is a clinical decision, made one patient at a time.

What about added ingredients like B12?

Some compounded products add vitamin B12. FDA's April 2026 update says adding B12 does not automatically make a product different. It may still count as a copy if the strengths match commercial products within 10%.

So an extra ingredient is not a loophole. The prescriber's documented reason matters more.

Outsourcing facilities follow a stricter path

Outsourcing facilities generally cannot compound from bulk ingredients unless the substance is on FDA's clinical need list, or the drug is on the shortage list. FDA says tirzepatide and semaglutide are on neither list right now.

In practice, that limits how these facilities can supply compounded GLP-1s.

Want a provider to explain your options?

telos rx is online-first and asynchronous. A licensed provider reviews your intake and replies by message, subject to medical approval by a licensed provider.

Explore GLP-1 options

Ingredients that cannot be compounded

Some GLP-1 related substances cannot be used in compounding at all. FDA's page on GLP-1 safety concerns names retatrutide and cagrilintide. Neither is a component of a drug with FDA approval, and FDA has warned companies marketing them.

If a website sells either one, see that as a serious warning sign.

Quality concerns FDA has flagged

FDA lists several problems it has seen with compounded GLP-1s:

  • Multi-dose vials used for longer than 28 days after first use.
  • Injectable medicine that arrives warm or with too little cold packing.
  • Fraudulent products with labels naming pharmacies that did not make them.
  • Ingredients from overseas makers with possible quality problems.

FDA set up an import alert to help stop poor-quality GLP-1 ingredients at the border. It says this does not create new limits on compounding that meets the rules.

Red flags when you shop online

FDA's consumer guidance lists warning signs. Walk away if a company:

  1. Says its compounded drug is the same as a branded one.
  2. Offers deep discounts or prices that seem too good to be true.
  3. Skips screening and a prescription by a licensed clinician.
  4. Has no licensed clinician to answer questions after you get your medicine.
  5. Sends medicine with spelling errors, wrong addresses or a pharmacy name you cannot verify.

How to check a provider yourself

You do not need a law degree. A few questions go a long way.

  • Which pharmacy prepares my medicine, and is it licensed in my state?
  • Can I look that pharmacy up with my state board of pharmacy?
  • Will a licensed clinician review my health history before prescribing?
  • Why is a compounded product right for me instead of a branded one?
  • How is the medicine shipped and kept cold?

For more, read our guide to comparing online GLP-1 providers.

Brand-name options are still worth checking

FDA says compounded drugs should only be used when a patient's needs cannot be met by a drug with FDA approval. So start with the brands. Check your insurance and the maker's own self-pay options.

Our compounded vs brand-name comparison lays out the differences. If you are new to the drug class, what is a GLP-1 covers the basics.

Why rules can change

Compounding policy moves with supply, court cases and new FDA guidance. A drug could return to the shortage list. FDA could issue new guidance. States can also update their own pharmacy rules.

Check FDA's pages, your state board of pharmacy and your provider before you start. Ask again if you see news about compounding.

How telos rx fits in

telos rx is an online-first, asynchronous telehealth service. You complete a private intake. A licensed provider reviews it and replies by message. There is nothing to schedule live.

Any compounded medication is not FDA-approved, and your provider sets every dose. Medication ships ready to inject. The GLP-1 options page listed pricing as low as $99 per month, as of 20 November 2026. Weigh the trade-offs in is a compounded GLP-1 worth it.

Talk it through with a licensed provider

Share your history and goals in a private online intake. A provider explains the options that may fit, subject to medical approval by a licensed provider.

Check my eligibility

Frequently Asked Questions

Is compounded semaglutide still allowed?

Compounding of semaglutide can continue only under federal compounding rules. Since FDA found the shortage resolved in February 2025, pharmacies may not regularly make products that are essentially copies of commercial drugs. A prescriber can document a significant clinical difference for a specific patient. Rules can change, so check FDA's page and ask your provider.

Is compounded tirzepatide still allowed?

The same framework applies. FDA found the tirzepatide shortage resolved in December 2024, and the transition windows have closed. A state-licensed pharmacy may compound for an individual patient with a valid prescription, but it may not regularly make essentially copies. Outsourcing facilities face stricter limits on bulk ingredients.

Do compounded GLP-1s have FDA approval?

No. Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness or quality before they are marketed. They share active ingredients with branded drugs but are different products. They should not be described as the same as, or better than, a branded medicine.

Who regulates compounding pharmacies?

State boards of pharmacy oversee most state-licensed compounding pharmacies day to day. FDA can also inspect them for surveillance or for cause. Outsourcing facilities register with FDA and are inspected on a risk-based schedule. NABP brings the state boards together and offers tools for checking online pharmacies.

Does adding B12 change the rules?

Not by itself. FDA's April 2026 reminder says a product that combines semaglutide with B12 may still count as essentially a copy if the strengths are within 10% of commercial products and the route is the same. A documented prescriber decision about a significant difference is what matters.

Could the rules change again?

Yes. A drug can return to FDA's shortage list, FDA can issue new guidance and courts or states can change things. We checked FDA's sources on 20 November 2026. Before starting or renewing a compounded GLP-1, check FDA's GLP-1 compounding page and ask your provider and pharmacy about current status.

telos rx is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. telos rx operates as an online-first, asynchronous telehealth service.

Ready to see if it fits? Start your private evaluation with telos rx.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX